RxDoctor Payments Data

Marc Barbella, DPM

Foot Surgery · Suffolk, VANPI 1154416352

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,663 of the $5,329 with a category attached, or 87.5%. 29 manufacturers reported payments, led by Stryker at 35.7% of the total. Reporting peaked in 2019 at $1,206 and has fallen 54.9% since, to $544 in 2025.

$5,329in general payments, 2019–2025

Across 129 payments — averaging $41.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Smith+Nephew$850
  • Organogenesis Inc.$340
  • KCI USA, Inc.$256
  • Kerecis Limited$235
  • Bioventus LLC$226
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$65612%
  • Food & beverage$4,66388%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,329 in reported general payments places this provider in the 75th percentile of 34 foot surgery providers in Virginia.

See all foot surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$183,117
Medicare patients
363
Services billed
2,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine32$884
Gabapentin62$333
Terbinafine Hcl14$247
Doxycycline Hyclate38$224
Cefdinir13$155
Meloxicam15$19

Paid to pharmacies, not to this prescriber.

Other foot surgery in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →